TABLE 2.
Final pathologic characteristics stratified by extent of the DCISM lesion
| DCISM suspected [n = 105] | DCISM definite 1 focus [n = 175] | DCISM definite >1 focus 1 biopsy [n = 67] | DCISM definite >1 focus >1 biopsy [n = 22] | p- Value | DCISM definite total [n = 264] | p-Value | |
|---|---|---|---|---|---|---|---|
| PT | <0.001 | <0.001 | |||||
| Tis | 54 (51) | 0 (0) | 0 (0.0) | 0 (0.0) | 0 (0) | ||
| T1mi | 22 (21) | 113 (65) | 36 (54) | 15 (68) | 164 (62) | ||
| Tl | 29 (28) | 60 (34) | 31 (46) | 7 (32) | 98 (37) | ||
| T2–4 | 0 (0) | 2 (1) | 0 (0) | 0 (0) | 2 (1) | ||
| Tumor size, cm [median (IQR)] | 0.2 (0.1–0.6) | 0.14 (0.1–0.4) | 0.2 (0.1–0.4) | 0.1 (0.1–0.4) | 0.71 | 0.17 (0.1–0.4) | 0.55 |
| pNa | 0.16 | 0.07 | |||||
| pN0 | 78/81 (96) | 147/163 (90) | 59/67 (88) | 18/22 (82) | 224/252 (89) | ||
| pN0(i+) | 2 (3) | 2 (1) | 0 (0) | 0 (0) | 2 (1) | ||
| pN1mi | 0 (0) | 4 (3) | 1 (2) | 2 (9) | 7 (3) | ||
| ≥pN1+ | 1 (1) | 10 (6) | 4 (6) | 2 (9) | 16 (6) | ||
| Extensive/multicentric DCIS | 17 (16) | 36 (21) | 11 (16) | 4 (18) | 0.79 | 51 (19) | 0.48 |
| Lymphovascular invasion | 5 (5) | 19 (11) | 4 (6) | 3 (14) | 0.33 | 26 (10) | 0.28 |
| Multicentric/multifocal invasive disease | 22 (21) | 61 (35) | 27 (40) | 16 (73) | <0.001 | 104 (39) | 0.001 |
| Estrogen receptor | 0.13 | 0.08 | |||||
| Positive | 69 (65) | 126 (72) | 51 (76) | 12 (55) | 189 (72) | ||
| Negative | 28 (27) | 43 (25) | 16 (23) | 9 (41) | 68 (26) | ||
| Not performed | 8 (8) | 6 (3) | 0 (0) | 1 (5) | 7 (3) | ||
| Progesterone receptor positive | 0.002 | 0.004 | |||||
| Positive | 35 (33) | 81 (46) | 36 (54) | 6 (27) | 123 (47) | ||
| Negative | 33 (31) | 54 (31) | 25 (37) | 11 (50) | 90 (34) | ||
| Not performed | 37 (35) | 40 (23) | 6 (9) | 5 (23) | 51 (19) | ||
| HER2-positive | <0.001 | <0.001 | |||||
| Positive | 12 (11) | 42 (24) | 24 (34) | 8 (36) | 73 (28) | ||
| Negative | 34 (32) | 69 (39) | 31 (46) | 8 (36) | 108 (41) | ||
| Not performed | 59 (56) | 64 (37) | 13(19) | 6 (27) | 83 (31) |
Data are expressed as n (%) unless otherwise specified
Percentages are rounded
DCISM ductal carcinoma in situ with microinvasion, IQR interquartile range, DCIS ductal carcinoma in situ, HER2 human epidermal growth factor receptor 2
a
Denominator = patients with axillary node assessment